MATHIESEN JEFFREY S 4

What Happened

• Jeffrey S. Mathiesen, a director of NeuroOne Medical Technologies Corp (NMTC), received equity awards reported on Form 4 for transactions dated April 3, 2026. The filing shows a grant of 41,929 restricted stock units (RSUs) and a 26,036-share derivative award (an option), each reported at $0.00 — total covered shares = 67,965. No cash was paid; these are awards/compensation, not open-market purchases or sales.

Key Details

• Transaction date: April 3, 2026; Form 4 filed April 7, 2026 (filed within the required 2 business days).
• Price reported: $0.00 for both entries (award/compensation).
• Vesting: F1 — the 41,929 RSUs vest in 12 equal monthly installments over one year; F2 — the 26,036 option vests in 12 equal monthly installments over one year.
• Shares owned after transaction: Not specified in the provided filing details.
• Nature: One award is RSUs (restricted stock units); the other is a derivative option award. These awards typically convert to owned shares only as they vest (and options may require exercise).

Context

• These grants are compensation awards and do not represent an open-market purchase or sale; they do not by themselves indicate that the insider bought or sold stock on the market. Vesting over 12 months means the awards will become exercisable/convert to shares gradually, which can lead to future share issuance or exercises depending on the award type.